June 16, 2021
Now available ADUHELM™
ADUHELM™ (aducanumab-avwa) injection, for intravenous use, is an amyloid beta-directed antibody indicated for the treatment of Alzheimer’s disease. This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).